

LIST OF PUBLICATIONS „PADMA 28“

Atherosclerosis (coronar, cerebral, peripher)

1. **Padma 28--a useful supplement in the treatment of peripheral arterial occlusive disease in the stages IIa and IIb.**
Regli C, Groechnig E. Forsch Komplementmed. 2013;20 Suppl 2:22-4.
2. **Clinical studies in peripheral arterial occlusive disease: update from the aspects of a meta-narrative review.**
Melzer J, Saller R. Forsch Komplementmed. 2013;20 Suppl 2:17-21.
3. **PADMA-28, a traditional tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants and pro-inflammatory agonists and peroxidation of lipids.**
Ginsburg I, Sadochnik M, Sallon S, Milo-Goldzweig I, Mechoulam R, Breuer A, Gibbs D, Varani J, Roberts S, Cleator E, Singh N. Inflammopharmacology. 1999;7(1):47-62.
4. **Treating intermittent claudication with Tibetan medicine Padma 28: does it work?**
Melzer J, Brignoli R, Diehm C, Reichling J, Do DD, Saller R. Atherosclerosis. 2006 Nov;189(1):39-46.
5. **Efficacy and safety of Padma 28 in peripheral arterial occlusive disease.**
Melzer J, Brignoli R, Saller R. Forsch Komplementmed. 2006 Feb;13 Suppl 1:23-7.
6. **Anti-inflammatory mechanisms of the Tibetan herbal preparation Padma 28 in the vessel wall.**
Exner M, Raith M, Holzer G, Gmeiner B, Wagner O, Kapiotis S. Forsch Komplementmed. 2006 Feb;13 Suppl 1:13-7.
7. **Complementary therapies for peripheral arterial disease**
Pittler MH, Ernst E. Atherosclerosis. 2005 Jul;181(1):1-7.
8. **PADMA-28, a traditional Tibetan herbal preparation, blocks cellular responses to bFGF and IGF-I.**
Navab R, Aingorn H, Fallavollita L, Sallon S, Mechoulam R, Ginsburg I, Vlodavsky I, Brodt P. Inflammopharmacology. 2004;12(4):373-89.
9. **Effects of the Tibetan herbal preparation PADMA 28 on blood lipids and lipid oxidisability in subjects with mild hypercholesterolaemia.**
Brunner-La Rocca HP, Schindler R, Schlumpf M, Saller R, Suter M. Vasa. 2005 Feb;34(1):11-7.
10. **A botanical compound, Padma 28, increases walking distance in stable intermittent claudication.**
Drabaek H, Mehlsen J, Himmelstrup H, Winther K. Angiology. 1993 Nov;44(11):863-7.
11. **Padma 28 modifies immunological functions in experimental atherosclerosis in rabbits.**
Gieldanowski J, Dutkiewicz T, Samochowiec L, Wójcicki J. Arch Immunol Ther Exp (Warsz). 1992;40(5-6):291-5.
12. **The efficacy of PADMA 28, a herbal preparation, in the treatment of intermittent claudication: a controlled double-blind pilot study with objective assessment of chronic occlusive arterial disease patients**
Sallon S, Beer G, Rosenfeld J, Anner H, Volcoff D, Ginsberg G, Paltiel O, Berlatzky Y
J Vasc Invest 1998;4/3:129-36.
13. **Case report: Padma 28 bei PAVK – Zwei Fälle aus der Praxis dokumentieren die Wirksamkeit**
Ditrych E, Béguin PA Ars Medici thema Phytotherapie. 2010;4/5:6-7.
14. **Treatment of chronic ischemia of the lower extremities with complex herbal preparation.**
Smulski HS. Ann Acad Med Stetin. 1991;37:191-202.
15. **Effects of the Tibetan herbal preparation Padma 28 in intermittent claudication.**
Schräder R, Nachbur B, Mahler F. Schweiz Med Wochenschr. 1985 Jun 1;115(22):752-6.
16. **Controlled double-blind study of PADMA-28 in angina pectoris.**
Wojcicki J, Samochowiec L Herba Polonica 1986;32/2:107-14.
17. **Effects of different calcium channel antagonists on the antinociceptive action of PADMA 28 in the writhing syndrome test in mice.**
Jagiello-Wojtowicz E, Kleinrok Z, Dolar J, Grzegorska I, Prokopiuk M, Chodkowska A Herba Polonica 1998;XLIV/4:379-82.

18. **Praxiserfahrungen mit einem Vielstoffpräparat aus der tibetischen Heilkunde, PADMA 28 - Retrospektive Fallstudie mit 147 Erfahrungsberichten [Practical experiences with a multi-compound preparation from Tibetan Medicine – PADMA 28: A retrospective case study with 147 practical-experience reports]**
Bommeli C, Bohnsack R, Kolb C Erfahrungsheilkunde 2001;50(11):745-56.
19. **In-Vitro-Untersuchungen mit PADMA 28: Hemmung der Thrombozytenfunktion**
[In vitro tests with PADMA 28: Inhibition of platelet function]
Altermatt R, von Felten A Schweiz Zschr GanzheitsMedizin 1992;4(7/8,Suppl.1):7–12.
20. **Periphere arterielle Verschlusskrankheit PAVK.**
Gröchenig E Schweiz. Zschr GanzheitsMedizin 2008;20:24-6.
21. **Behandlung der Claudicatio intermittens mit Padma 28.**
Gröchenig E Gefässmedizin.net 2007;3:76-7.
22. **The role of regulatory systems in inflammatory heart disease. Application of Padma 28, an immunomodulatory herbal drug, in auxiliary therapy of heart diseases.**
Zebrowski MR Kardiologia, Rheumatologia 2002;9:11-4.
23. **Modification of antinociceptive action of PADMA 28 by endogenous nitric oxide in mice.**
Jagiello-Wojtowicz E, Kleinrok Z, Chodkowska A, Szponar J Pol J Pharmacol 1998;50/Suppl.:135
24. **Effect of PADMA 28 on ascorbate system in rats receiving a high-fat diet.**
Wojcicki J, Gonet B, Samochowiec L, Gnacinska K, Juzwiak S Phytother Res 1989;3/2:54-6.
25. **Clinical studies on the efficacy and safety of Padma 28, a complex herbal formulation from Tibetan medicine: an overview.**
Vennos C, Melzer J, Saller R. Forsch Komplementmed. 2013;20 Suppl 2:25-30.

Diabetes mellitus

1. **Pathogenese und pleiotrope Behandlungsansätze bei diabetischer Folgeerkrankungen – Übersicht über Wirkmechanismen von Padma 28**
Vennos C, Loepfe C Schweiz Z Ganzheitsmed. 2014;26:227-233.

Rheumatoid arthritis

1. **PADMA 28 in the therapy of rheumatoid arthritis. A 6-month clinical and laboratory study.**
Bernacka K, Sierakowski St, Brzosko WJ
Abstract; 4th Interscience World Conference on Inflammation, Geneva / Switzerland, 1991; April 15-18
2. **Influence of PADMA 28 and thymus extract on clinical and laboratory parameters of children with juvenile chronic arthritis.**
Brzosko WJ, Jankowski A, Prusek W, Ollendiek H Int. Journal of Immunotherapy 1991;VII/3:143-7.

Antiinflammatory / Immunomodulatory / Antioxidative

1. **Inhibitory actions of selected natural substances on formation of advanced glycation endproducts and advanced oxidation protein products.**
Grzebyk E, Piwowar A BMC Complement Altern Med. 2016 Sep 29;16(1):381.
2. **PADMA 28 modulates interferon-gamma induced tryptophan degradation and neopterin production in human PBMC in vitro**
Neurauter G, Wirleitner B, Schroecksnadel K, Schennach H, Ueberall F, Fuchs D
Int Immunopharmacol 2004 Jun;4(6):833-9.
3. **Angiomodulatory properties of Rhodiola spp. and other natural antioxidants.**
Radomska-Leśniewska DM, Skopiński P, Bałan BJ, Białoszewska A, Józwiak J, Rokicki D, Skopińska-Różewska E, Borecka A, Hevelke A Cent Eur J Immunol. 2015; 40(2):249-62.
4. **The effect of anti-inflammatory and antimicrobial herbal remedy PADMA 28 on immunological angiogenesis and granulocytes activity in mice.**
Radomska-Leśniewska DM, Skopiński P, Niemcewicz M, Zdanowski R, Lewicki S, Kocik J, Skopińska-Różewska E, Stankiewicz
Mediators Inflamm. 2013;2013:853475.

5. **In vivo stimulatory effect of multi-component herbal remedy PADMA 28 on mitogen-induced proliferation of mice splenic lymphocytes and their chemokinetic activity.**
Skopiński P, Radomska-Leśniewska DM, Sokolnicka I, Balan BJ, Siwicki AK, Skopińska-Różewska E.
Pol J Vet Sci. 2013;16(4):701-5.
6. **The Aging Immune System and Chronic Diseases: Acupuncture, Extracellular Matrix and the Herbal Formula Padma 28 in the Framework of a Structured Prevention and Therapy Concept**
Schwabl H, Vennos C Dt Ztschr F Akup 2011;54:16-20.
7. **A multi-component herbal preparation (PADMA 28) improves structure/function of corticosteroid-treated skin, leading to improved wound healing of subsequently induced abrasion wounds in rats.**
Aslam MN1, Warner RL, Bhagavathula N, Ginsburg I, Varani J. Arch Dermatol Res. 2010 Nov;302(9):669-77.
8. **Inflammaging - Altern als Konsequenz chronischer Entzündungen: Das Beispiel Padma 28**
Ginsburg I, Vennos C, Koren E Schweiz Zschr GanzheitsMedizin 2008; 20(7/8): 412-7.
9. **Systemisch limitierte Sklerodermie - Therapieoption mit Padma 28 in einem klinisch fortgeschrittenen Stadium.**
Kappler S Schweiz Zschr GanzheitsMedizin 2008;20:345-6.
10. **PADMA-28, a Tibetan herbal preparation is an inhibitor of inflammatory cytokine production.**
Barak V, Kalickman I, Halperin T, Birkenfeld S, Ginsburg I. Eur Cytokine Netw. 2004 Jul-Sep;15(3):203-9.
11. **Inhibition of inducible nitric oxide synthesis by the herbal preparation Padma 28 in macrophage cell line.**
Moeslinger T, Friedl R, Volf I, Brunner M, Koller E, Spieckermann PG
Can J Physiol Pharmacol. 2000 Nov;78(11):861-6.
12. **Anti- and pro-oxidative properties of PADMA 28, a Tibetan herbal formulation.**
Suter M, Richter C. Redox Rep. 2000;5(1):17-22.
13. **The therapeutic effect of an herbal formula Badmaev 28 (padma 28) on experimental allergic encephalomyelitis (EAE) in SJL/J mice.**
Badmaev V, Kozłowski PB, Schuller-Levis GB, Wisniewski HM. Phytother Res. 1999 May;13(3):218-21.
12. **The effect of Padma-28, a traditional Tibetan herbal preparation, on human neutrophil function.**
Matzner Y, Sallon S. J Clin Lab Immunol. 1995;46(1):13-23.
13. **Immunostimulation in recurrent respiratory tract infections therapy in children.**
Prusek W, Jankowski A, Radomska G, Wieczorek E, Podwysocka M
Arch Immunol Ther Exp 1987;35:289-302.
14. **Treatment with PADMA 28 of children with recurrent infections of the respiratory tract**
Jankowski A, Drabik E, Szysko Z, Stasiewin W, Brzosko WJ Therapiewoche Schweiz 1986;2/1:25-32.
15. **Wirkung von Padma 28 auf das Immunsystem bei Patienten mit Aquired Immunodeficiency Syndrom im Stadium des Pre-Aids: Klinische Bewertung einer Pilot-Studie.**
Schweiz Zschr GanzheitsMedizin 1990; 2: 58-62.
16. **Prolonged steady state in pre-AIDS patients treated with an immunoactive drug, PADMA 28.**
De Bac C, Caprilli F International Congress for Infectious Diseases, April 17-21, 1988, Rio de Janeiro

Hepatitis

1. **Influence of Padma 28 on the activity of alpha-mannosidase and alpha-fucosidase in the serum of alcohol-dependent men.**
Zaniewska A, Gil A, Romatowski J, Szajda SD, Stypulkowska A, Prokop I, Dobryniewski J, Zwierz K.
Exp Clin Hepatol. 2008;4(3-4):43-5.
2. **Mode of action: hepatoprotective; immunomodulatory Treatment of patients with active liver cirrhosis with PADMA 28**
Hryniewiecki L, Brzosko WJ, Klincewicz H, Stachowiak Cz
3. **Influence of PADMA 28 on patients with chronic active hepatitis B.**
Gładysz A, Juszczak J, Brzosko WJ Phytother Res 1993;7:244-7.
4. Schweiz Zschr für GanzheitsMed 1992;4(Suppl 1):13-4.

PADMA 28 in patients with chronic hepatitis B: Clinical and immunological effects

Brzosko WJ, Jankowski A

5. Abstract; 19th Int. Congress of Pediatrics, Paris / France, 1989
Treatment with PADMA 28 of children with chronic active hepatitis infected with HBV
Brzosko WJ, Debski R, Wisniewska W, Jankowski A
6. Study report / Personal communication, Institute of tropical diseases, University "La Sapienza", Rome 1988, Nov, p.1-3
Effects of a herbal drug, PADMA 28, on HBV replication in chronic HBsAg carriers
Taliani G, Clementi C, Lecce R, Colloca S, Grimaldi F, De Bac C
7. Biologische Medizin 1986;15/6:300-5.
PADMA 28 in the treatment of chronic active hepatitis
Brzosko WJ, Gladysz A, Juszczyk J
8. **Significant reduction of viral activity in carriers of HBs after receiving an herbal drug with immunomodulant effect.**
De Bac C, Taliani G, Furlan C, Bernaschi P J Hepatol 1985;Suppl.1:46

Cancer

1. **Apoptosis induced by the Tibetan herbal remedy PADMA 28 in the T cell-derived lymphocytic leukaemia cell line CEM-C7H2.**
Jenny M, Schwaiger W, Bernhard D, Wrulich OA, Cosaceanu D, Fuchs D, Ueberall F.
J Carcinog. 2005 Sep 2;4:15.
2. **Padma 28 in cytostatic-induced dysesthesia and edema of the hands--a case from practice.**
Kneip B. Forsch Komplementmed. 2013;20 Suppl 2:33-4.
3. **Pflanzliches Vielstoffgemisch unterstützt synthetische Krebstherapie.**
Cristiane Class Schweiz.Zschr. GanzheitsMedizin 2005;17 382-387

Dentistry

1. **Padma 28 in the treatment of chronic dental pulpitis: an observational case study in 49 patients.**
Fülleemann F Forsch Komplementmed. 2006 Feb;13 Suppl 1:28-30. Epub 2006 Feb 17.

Neurology

1. **Current Complementary and Alternative Therapies for Multiple Sclerosis.**
Bowling AC, Stewart TM. Curr Treat Options Neurol. 2003 Jan;5(1):55-68.
2. **Cerebraler Insult: Prävention, Verlauf und Prognose - Welchen Einfluss hat das Tibetische Arzneimittel Padma 28?**
Allemann D. Schweiz Zschr GanzheitsMedizin 2007; 19(3): 142-5.
3. **Experience of PADMA 28 in Multiple Sclerosis.**
Korwin-Piotrowska T, Nocon D, Stankowska-Chomicz A, Starkiewicz A, Wojcicki J, Samochowiec L
Phytother Res 1992;6:133-6.
4. **Multiple Sklerose: Komplementär-medicinische und alternative Therapien.**
Schweiz Zschr GanzMed 2003;15(4):197-9.
5. **Influence of selected immunocorrecting drugs on intellectual function of the brain due to arteriosclerosis.**
Panjwani HK, Brzosko WJ Nowiny Lekarskie (Medical News) 1998;5:665-70.
6. **Clinical evaluation of PADMA 28 in treatment of senility and other geriatric circulatory disorders: a pilot study.**
Panjwani HK, Priestley MD Study report / Personal communication, New Jersey 1986, p.1-15
7. **The herbal preparation Padma® 28 protects against neurotoxicity in PC12 cells.**
Ginsburg I1, Rozenstein-Tsalkovich L, Koren E, Rosenmann H. Phytother Res. 2011 May;25(5):740-3.